Additionally, tsMHC-II-presented tumor neoantigens have more stable mutations, suggesting that tsMHC-II and CD4 + T cells play a more deep-seated role in anti-tumor immune surveillance than previously thought [30]. This evidence concerns the gene CD4 and neoplasm.